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ABSTRAK
Background: Methods used to diagnose and monitor chronic hepatitis B (CHB) by quantitation of hepatitis 
B virus-deoxyribonucleic acid (HBV-DNA) levels is expensive. Cheaper laboratory test as an additional marker 
is needed, thus we studied serum quantitative HBsAg to be used as surrogate marker in CHB patients. This 
study was aimed to investigate correlation between serum quantitative HBsAg and HBV-DNA in CHB patients. 
Method: In this cross-sectional study, we enrolled 62 CHB patients between January 2010 and December 2012 
who had quantitative HBsAg and HBV-DNA assays in a private laboratory at Denpasar. HBV-DNA was measured 
by real-time polymerase chain reaction and quantitative serum HBsAg was measured by chemiluminescent 
microparticle immunoassay (CMIA). Stastistical analysis was performed by Mann-Whitney and Spearman’s 
correlation.
Results: Of 62 patients, most subjects were males (82.26%). Mean HBsAg titer of CHB in HBeAg positive 
and negative patients were 281,000 and 4,900 IU/mL, respectively; while mean HBV-DNA in HBeAg positive 
and negative patients were 59,000,000 and 7,530,000 IU/mL, respectively. We found that quantitative HBsAg 
and HBV-DNA in HBeAg positive and HBeAg negative patients were statistically signi cant (p = 0.0001,
 p = 0.0001, respectively). Signi cant correlation was found between serum quantitative HBsAg and HBV-DNA 
(r = 0.737; p= 0.000). Quantitative HBsAg was signi cantly correlated with HBV-DNA in HBeAg-positive 
subgroup (r = 0.717; p = 0.0001); and signi cant correlation was also found in HBeAg-negative subgroup 
(r = 0.443; p = 0.006) although the correlation was weak. 
Conclusion: Quantitative HBsAg has signi cant correlation with HBV-DNA in CHB patients. 
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ABSTRAK
Latar belakang: Metode yang digunakan untuk diagnosis dan memantau hepatitis B kronis menggunakan 
kadar deoxyribonucleic acid-virus hepatitis B (DNA-VHB) secara kuantitatif masih cukup mahal. Saat ini 
masih  dibutuhkan pemeriksaan laboratorium yang lebih murah sebagai petanda tambahan. Hal tersebut yang 
mendorong kami untuk melakukan penelitian mengenai HBsAg serum kuantitatif yang dapat digunakan sebagai 
petanda pengganti pada pasien hepatitis B kronis. Penelitian ini bertujuan untuk mengetahui korelasi antara 
serum HBsAg kuantitatif dan DNA-VHB pada pasien hepatitis B kronis. 
Metode: Desain penelitian potong lintang dilakukan pada 62 pasien hepatitis B kronis dari Januari 2010 
sampai Desember 2012 yang menjalani pemeriksaan HBsAg kuantitatif dan DNA-VHB di laboratorium swasta, 
Denpasar. DNA-VHB diukur menggunakan real-time polymerase chain reaction, dan serum HBsAg kuantitatif 
diukur dengan chemiluminescent microparticle immunoassay (CMIA). Analisis statistik dilakukan dengan uji 
Mann-Whitney dan korelasi Spearman.
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Hasil: Dari 62 pasien, sebagian besar adalah pria (82,26%). Rerata titer HBsAg pada pasien hepatitis B 
kronis dengan HBeAg positif dan negatif masing-masing adalah 281.000 dan 4.900 UI/mL; sedangkan rerata 
DNA-VHB pada pasien dengan HBeAg positif dan negatif masing-masing adalah 59.000.000 dan 7.530.000 
UI/mL. HBsAg kuantitatif dan DNA-VHB pada pasien dengan HBeAg positif dan HBeAg negatif ditemukan 
berbeda bermakna (p = 0.0001). Korelasi bermakna juga ditemukan antara serum HBsAg kuantitatif dengan 
DNA-VHB (r = 0,737; p = 0,000). HBsAg kuantitatif berkorelasi bermakna dengan DNA-VHB pada kelompok 
HBeAg positif (r = 0,717; p = 0,0001); korelasi bermakna juga ditemukan pada kelompok HBeAg negatif (r = 
0,443; p = 0,006) meskipun korelasinya lemah.
Simpulan: HBsAg kuantitatif memiliki korelasi bermakna dengan DNA-VHB pada pasien hepatitis B kronis. 
Kata kunci: pemeriksaan HBsAg kuantitatif, DNA-VHB, HBeAg, infeksi hepatitis B kronis 
INTRODUCTION
Hepatitis B virus (HBV) causes a wide range 
of clinical consequences, from acute and chronic 
infection till cirrhosis and hepatocellular carcinoma, 
and represents a global public health problem.1,2 Level 
of HBV-DNA, alanine aminotransferase (ALT), and 
histological  ndings are important to determine HBV 
treatment. Active viral infection can be detected by 
HBV-DNA level but this assay is expensive. Therefore, 
cheaper laboratory test that can be used as surrogate 
marker is needed.3
Quantitative HBsAg is believed might be helpful in 
the management of HBV. This assay can be used as a 
biomarker to evaluate infection treatment response in 
chronic hepatitis B (CHB). HBsAg level re ects the 
transcriptional activity of covalently closed circular 
DNA (cccDNA) rather than the absolute amount of 
cccDNA copies.4 
Various studies have shown the clinical utility 
of HBsAg quantitation, but studies where these two 
markers have been compared are scarce, with con icting 
results.5-10 Therefore, the present study was undertaken 
to  nd correlation between HBV DNA and quantitative 
HBsAg in CHB patients. 
METHOD
A cross-sectional study was performed in 62 CHB 
patients consecutively between 2010 and 2012 who 
had quantitative HBsAg and HBV-DNA assays in 
a private laboratory in Denpasar, Bali. All chronic 
HBV patients, with HBeAg positive and negative who 
underwent quantitative HBsAg and HBV-DNA assays 
were included. 
HBV-DNA was measured by real-time polymerase 
chain reaction with limit of detection 20 IU/ml 
(conversion: 1 IU is equivalent to 5.82 copies/mL), 
measuring range of 20-170,000,000 IU/mL, speci city 
100%. Quanti cation of HBsAg was performed using 
the ArchitectTM HBsAg assay, a two-step immunoassay 
based on the use of chemiluminescent microparticles 
immunoassay (CMIA). To determine human serum and 
plasma HBsAg concentrations quantitatively, CMIA 
with  exible assay protocols, referred to as Chemi ex, 
was used. In the  rst step, the sample and hepatitis 
B surface antigen antibody (anti-HBs) coated with 
paramagnetic microparticles are combined. HBsAg 
present in the sample binds to the anti-HBs coated 
microparticles. After washing, acridinium-labeled 
anti-HBs conjugate is added. Following another wash 
cycle, pre-trigger and trigger solutions are added to 
the reaction mixture. The resulting chemiluminescent 
reaction is measured as relative light units (RLUs). 
A direct relationship exists between the amount of 
HBsAg in the sample and the RLUs detected by the 
Architect Immunoassay System optics. This is a fully 
automated system and can detect as low as 0.2 ng/mL 
of HBsAg with a dynamic range of 0.05-250 IU/mL.
Continuous variables were compared between 
groups using Mann-Whitney test. Spearman’s 
correlation was used because variables were not 
normally distributed. We used 95% con dence interval 
with signi cance level of 0.01 (2-tailed). All statistical 
analyses were performed using SPSS.
RESULTS
Of 62 patients, 51 (82.26%) were male and 11 
(17.7%) were female. Mean age of subjects was 
42.34 ± 13.07 years. Mean HBsAg titer in CHB with 
HBeAg positive and negative patients were 281,000 
and 4,900 IU/mL, respectively; while mean HBV-DNA 
in HBeAg-positive patients and HBeAg-negative 
patients were 59,000,000 and 7,530,000 copies/mL, 
respectively (Table 1).
We found that quantitative HBsAg and HBV-DNA 
in HBeAg-positive and HBeAg-negative patients 
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were statistically different (p = 0.0001, p = 0.0001, 
respectively) (Table 1). Signi cant correlation was 
found between serum quantitative HBsAg and HBV-
DNA (r = 0.737; p = 0.0001). Quantitative HBsAg was 
signi cantly correlated with HBV-DNA in HBeAg-
positive subgroup (r = 0.717; p = 0.000). Similarly, 
signi cant correlation was also found in HBeAg-
negative subgroup (r = 0.443; p = 0.006), although the 
correlation was weak (Table 2). 
DISCUSSION 
This study results showed signi cant and strong 
correlation between quantitative HBsAg and HBV-
DNA. But in subgroups, HBsAg had strong correlation 
with HBV-DNA in HBeAg-positive CHB group, while 
the correlation was found weak in HBeAg-negative 
group. Thompson et al, showed similar results in 
HBeAg-positive CHB group, in which HBsAg had 
strong correlation with HBV-DNA (r = 0.69; p < 0.01), 
while in HBeAg-negative CHB group, HBsAg had 
weak correlation with HBV-DNA (r = 0.28; p = 0.01).11 
Gupta et al, found weak but signi cant correlation 
between quantitative HBsAg and HBV-DNA in all 
the groups (r = 0.443; p < 0.01); this correlation 
was stronger in HBe antigen-positive (r = 0.402; 
p < 0.01).12 Similarly, Lee et al, demonstrated that the 
overall correlation between quantitative HBsAg and 
HBV DNA was signi cant but very weak (r = 0.121; 
p = 0.004).13 Chan et al, showed that quantitative 
HBsAg correlated well with log [cccDNA] (r = 0.54; 
p = 0.004) and log [total intrahepatic HBV DNA] 
(r = 0.43, p = 0.028).7 In contrast, Ganji et al, 
demonstrated no significant correlation between 
HBsAg and HBV-DNA (r = 0.53, p = 0.606).3 
Hepatitis B virus, a small DNA virus, is a prototype 
virus of the Hepadnaviridae family. HBV infection 
leads to a wide spectrum of liver diseases ranging from 
acute to chronic hepatitis, cirrhosis, and hepatocellular 
carcinoma.14 Upon entry into the hepatocyte nucleus, 
the host and viral polymerase repair the partially 
double-stranded HBV genome to a fully double-
stranded (cccDNA), which as a non-integrated 
minichromosome, acts as a template for transcription 
of viral genes.15 Assay of cccDNA in liver tissue is the 
most accurate index of infected hepatocytes but the 
complexity of the testing renders it unavailable for 
routine use. Serum HBsAg has been shown to correlate 
with transcriptionally active cccDNA.16
Measuring serum HBV-DNA is the gold standard 
for monitoring viral load, but it is relatively expensive 
and not yet readily available in some areas. Hence, 
there is a de nite need of a tool which is economical, 
reliable, and easy to perform. HBsAg quantitation is 
a recent serological marker being evaluated.17 The 
technique for detecting quantitative HBsAg is fairly 
easy and inexpensive.18 The  rst assay for quantitative 
HBsAg using enhanced chemiluminescence was 
reported nearly 20 years ago but was limited by lack 
of standardization.15 Serum HBsAg quanti cation has 
been suggested to re ect the concentration of cccDNA 
in the liver which serves as the template for viral 
replication inside hepatocytes.19,20
Table 1. Baseline subject characteristics
Parameters Patients (%) Mean ± SD p*
Age (years) 42.34 ± 13.07
Sex
Male
Female 
51 (82.3)
11 (17.7)
HBeAg-positive CHB
HBsAg titer (IU/mL)
HBV-DNA (copies/mL)
25 (40.32)
2.81 x 105 ± 1.3 x 106
5.9 x 107 ± 5.45 x 107 0.0001*
HBeAg-negative CHB
HBsAg titer (IU/mL)
HBV-DNA (copies/mL)
37 (59.68)
4.9 x 103 ± 2.05 x 104
7.53 x 106 ± 2.55 x 107 0.0001*
*Mann-Whitney; CHB: chronic hepatitis B; HBV-DNA: hepatitis B virus-deoxyribonucleic acid
Table 2. Statistical analysis for correlation between quantitative HBsAg and HBV-DNA
Mean (95% CI)
r p*HBsAg
(IU/mL)
HBV-DNA
(copies/mL)
All Subject 1.16 x 105 2.83 x 107 0.737 0.000
HBeAg positive (n = 25) 2.81 x 105 5.9 x 107 0.717 0.000
HbeAg negative (n = 37) 4.9 x 103 7.53 x 106 0.443 0.006
*Spearman’s correlation test; HBV: hepatitis B virus; signi cant at the 0.01 level (2-tailed); HBV-DNA: hepatitis B virus-deoxyribonucleic acid
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HBsAg is encoded by the envelope gene, which 
contains three open-reading frames: the pre-S1, pre-S2 
and S domains. There is subsequent conversion to 
small, medium and large forms of HBsAg proteins. 
Newly synt hesized HBsAg proteins are secreted from 
the hepatocyte. HBsAg synthesis is separated from the 
viral replication pathway. Existent quantitative HBsAg 
serology can detect all three forms of HBsAg in the 
circulation.12
Based on the results of this study and the discussion 
above, we can consider quantitative HBsAg as a 
surrogate marker to HBV-DNA. Limitation of this 
study was the relatively small number of patients.
CONCLUSION
Quantitative HBsAg has signi cant correlation 
with HBV-DNA in CHB patients. Further studies 
are required to investigate the possibility of using 
quantitative HBsAg as an aid, if not an alternative, 
for HBV-DNA.
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